# A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

Study · id `cardio:ct-nct03766581` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03766581](<https://clinicaltrials.gov/study/NCT03766581>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03766581

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2366 participants.

## Technical summary

Registry record NCT03766581. Randomized; quadruple masking; primary purpose prevention. Start 2019-01-27 (actual); primary completion 2022-03-31 (actual). Results posted on 2023-06-12.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 2366 participants (enrolled count; ClinicalTrials.gov record NCT03766581, source copy `cardio:ctgov-nct03766581-2023-06-12`, retrieved 2026-10-26)
- Started: 2019-01-27 (actual) (ClinicalTrials.gov record NCT03766581, source copy `cardio:ctgov-nct03766581-2023-06-12`, retrieved 2026-10-26)
- Primary completion: 2022-03-31 (actual) (ClinicalTrials.gov record NCT03766581, source copy `cardio:ctgov-nct03766581-2023-06-12`, retrieved 2026-10-26)
- Completion: 2022-03-31 (actual) (ClinicalTrials.gov record NCT03766581, source copy `cardio:ctgov-nct03766581-2023-06-12`, retrieved 2026-10-26)
- Results first posted: 2023-06-12 (ClinicalTrials.gov record NCT03766581, source copy `cardio:ctgov-nct03766581-2023-06-12`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Czechia; Denmark; Finland; France; Germany; Greece; Hong Kong SAR China; Hungary; Israel; Italy; Japan; Mexico; Norway; Poland; Russia; South Korea; Spain; Sweden; Switzerland; United Kingdom (ClinicalTrials.gov record NCT03766581, source copy `cardio:ctgov-nct03766581-2023-06-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03766581-2023-06-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
- Acronym: AXIOMATIC-SSP
- Condition: Acute Ischemic Stroke
- Condition: Transient Ischemic Attack (TIA)
- Intervention (Drug): BMS-986177
- Intervention (Other): Placebo
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Aspirin
- Lead sponsor: Bristol-Myers Squibb
- Lead sponsor class: INDUSTRY
- Collaborator: Janssen, LP
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Transient ischemic attack (mini-stroke) (`cardio:transient-ischemic-attack`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial (`cardio:pubmed-38101902`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e71004eb0efabb464b7dc81a9aa6542b79e978553344e949ecb4b6fa4c294d11
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
